TP53 and breast cancer: Indeed, we posited that the TP53 clique module, although derived from the perturbation signature in ER+ breast cancer, would exhibit a higher signature score in cancer tissue compared to normal samples: we note that since the original in vitro perturbation signature measures deactivation, that a higher signature score in cancer is consistent with a higher frequency of inactivation in the neoplasias.